Compare TSAT & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSAT | AQST |
|---|---|---|
| Founded | 1969 | 2004 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 697.5M | 504.0M |
| IPO Year | 2021 | 2007 |
| Metric | TSAT | AQST |
|---|---|---|
| Price | $44.44 | $3.96 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $37.00 | $9.00 |
| AVG Volume (30 Days) | 217.5K | ★ 1.8M |
| Earning Date | 05-05-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,430,000.00 |
| Revenue This Year | N/A | $10.08 |
| Revenue Next Year | N/A | $49.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.77 |
| 52 Week Low | $15.90 | $2.94 |
| 52 Week High | $59.12 | $7.55 |
| Indicator | TSAT | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 41.55 | 43.48 |
| Support Level | $43.00 | $3.70 |
| Resistance Level | $56.88 | $4.38 |
| Average True Range (ATR) | 4.61 | 0.15 |
| MACD | -1.12 | -0.02 |
| Stochastic Oscillator | 3.61 | 23.86 |
Telesat Corp is a satellite operator, that provides its customers with mission-critical communications services. It operates in a single operating segment, in which it provides satellite-based services to its broadcast, enterprise, and consulting customers around the world. The company has two operating segments: GEO services (GEO) segment that refers to the operation of the fleet of GEO satellite and LEO services (LEO) segment that refers to the deployment and operation of the Telesat Lightspeed constellation Geographically, it derives a majority of its revenue from Canada. It derives revenue from Broadcast, Enterprise, Consulting, and others.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.